CXM Cardium Therapeutics Inc., Ends trading session at 1.85
Cardium Therapeutics Inc.
StockEinstein.com offers free trading alerts on stocks about to run. To sign up for our free alert service please click here www.stockeinstein.com or scroll to bottom of this page to sign up.
Last Trade: 1.85 Day's Range: 1.75 - 1.90 Trade Time: 4:02pm ET 52wk Range: 0.38 - 3.10 Change: Up 0.05 (2.78%) Volume: 142,919 Prev Close: 1.80 Avg Vol (3m): 164,950 Open: 1.80 Market Cap: 87.51M About Cardium Therapeutics Inc.
Cardium Therapeutics, Inc. (Cardium) is a medical technology development-stage company. The Company is primarily focused on the development, manufacture and sale of therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium owns a portfolio of biologic growth factors and related delivery techniques, acquired from the Schering AG Group, for potential use in treating ischemic and other cardiovascular conditions. Cardium owns rights to the assets and technologies of Tissue Repair Company, a company focused on the development of growth factor therapeutics for the potential treatment of tissue wounds, such as chronic diabetic wounds. Tissue Repair Company is operated as a wholly owned subsidiary of Cardium. In July 2009, the Company completed the asset sale of its InnerCool Therapies business to Koninklijke Philips Electronics NV.
About StockEinstein
StockEinstein.com uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
Thank you for your interest in Findit News. A member of the Findit News team will contact you soon to show you how you can take your marketing to the next level with press releases on Findit.
